Compare Biogen Inc (BIIB) vs Motorola Solutions Inc (MSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Motorola Solutions Inc — how do they compare? Biogen Inc trades at $205.98 (market cap $30.13B), while Motorola Solutions Inc trades at $465.49 (market cap $77.26B). The key difference: Motorola Solutions Inc is far larger — about 2.6× Biogen Inc's market cap, and Motorola Solutions Inc pays a 1.04% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MSI | |
|---|---|---|
Market Cap | $30.13B | $77.26B |
Sector | Health | Technology |
52-Week High | $216.63 | $490.30 |
52-Week Low | $128.93 | $363.83 |
Enterprise Value | $37.20B | $86.17B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
Motorola Solutions (MSI) trades at $461.98, down 1.19% today but has demonstrated strong momentum with three consecutive quarterly earnings beats and a 23.5% gain over three months. The company reported record Q2 2026 results with 13% revenue growth and raised full-year guidance, supported by a record $15.6 billion backlog. Technical indicators show a bullish trend with the stock near its pivot point of $463, while valuation metrics remain elevated with a P/E of 36.79.
The outlook remains positive given strong demand in public safety communications and software services, with analyst consensus pointing to 15% upside to the $533.80 price target. Key risks include execution challenges to meet elevated expectations and the premium valuation requiring sustained high growth. The combination of operational strength and bullish sentiment supports a constructive view for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →
